Pregabalin Capsule
Product Images NDC 50268-501

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50268-501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (497 01)

FDA Label Image

1 (498 01)

FDA Label Image

1 (499 01)

FDA Label Image

1 (500 01)

FDA Label Image

1 (501 01)

FDA Label Image

1 (Table 5)

This text includes a tabulated list of adverse events associated with the consumption of different doses of AIPGB (PGB: pregabalin), along with a placebo. The adverse events are categorized based on body system and preferred terms. Some commonly reported adverse events include headache, pain, dry mouth, constipation, weight gain, dizziness, somnolence, and blurry vision. The text also mentions that "Thinking abnormal" primarily involves difficulties with concentration/attention, cognitive issues, language problems, and slowed thinking. This information can be useful for evaluating the potential side effects of AIPGB and understanding the impact on various body systems.*

FDA Label Image

Equation (Pregabain Gault Equation)

The text provides a formula for calculating creatinine clearance (CLCr) based on the patient's age, weight, and serum creatinine level. The formula includes different coefficients based on gender, with a reduced factor (0.85) for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This is a chart showing the percentage of patients who improved based on different doses of Pregabalin and a placebo. The chart indicates the level of improvement in pain from baseline for each treatment option.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This text presents a graph showing the percentage of patients who improved with Pregabalin 100 mg three times a day compared to the placebo in terms of pain relief. The graph illustrates a scale from 0% to 100% improvement in pain from the baseline.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This text describes the percentage of patients who experienced improvement in pain levels with different doses of Pregabalin and a placebo. The chart shows the increasing percentage of patients reporting improvement from baseline pain levels for various dosages of Pregabalin and a placebo. The effectiveness of Pregabalin at different doses can be inferred from the data presented in the chart.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This is a chart displaying the percentage of patients improved with different dosages of pregabalin and placebo, along with the percentage of improvement in pain from baseline. The chart suggests that higher dosages of pregabalin result in increased improvement in pain compared to a placebo.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This is a data table showing the percentage of patients who improved with different treatments. The treatments listed include Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo. The table also shows the percentage improvement in pain from baseline, ranging from over 10% to over 90%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This is a table showing responder rates for different doses of a medication in two studies (E1 and E3). The responder rates are presented as percentages for different dosages ranging from 9% to 60%. The table indicates that some dosages are statistically significant compared to the placebo. The study compared different dosages of the medication, and the number of responders is shown for each dosage in both studies.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This -text provides statistical data related to the significance levels of different doses administered, with notable p-values indicating the significance of the results. The doses are represented in mg/day, and the analysis includes multiple T and B values, as well as data regarding Stukly E1BID, E2BID, E3BID, and E3TID. The information also includes the comparison of placebo doses with other doses within the study.*

FDA Label Image

Pregabalin-figure-08 (Pregabalin Figure 08)

This text includes percentages related to a responder rate, as well as different values such as 406%, 2.1%, 26%, and 93-103%. It also mentions different dosages (25 mg/kg/day and 10 mg/kg/day) for a placebo.*

FDA Label Image

Pregabalin-figure-09 (Pregabalin Figure 09)

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This appears to be a table depicting the estimated percentage of subjects without low insulin resistance (LIR) for different levels of Pregabalin and Placebo. It shows the data across various percentages as well as days. The table seems to be used for evaluating the impact of Pregabalin on subjects with LIR.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This description provides data on the percentage of subjects who improved from baseline to week 12 for Pregabalin compared to Placebo. The graph shows the distribution of improvements across different percentage ranges from 0 to 100.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This text provides information on the percentage of subjects who improved over the course of a study involving the use of Pregabalin compared to Placebo from baseline to week 16. It also includes a chart with percentage ranges of improvement.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.